Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
This study has been completed.
Sponsor:
University of Pennsylvania
Collaborator:
Genentech
Information provided by (Responsible Party):
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00472693
First received: May 11, 2007
Last updated: January 31, 2013
Last verified: January 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | April 2011 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |